» Articles » PMID: 23574944

Continuous Controversy About Radiation Oncologists' Choice of Treatment Regimens for Bone Metastases: Should We Blame Doctors, Cancer-related Features, or Design of Previous Clinical Studies?

Overview
Journal Radiat Oncol
Publisher Biomed Central
Specialties Oncology
Radiology
Date 2013 Apr 12
PMID 23574944
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies from Italy, Japan and Norway have confirmed previous reports, which found that a large variety of palliative radiotherapy regimens are used for painful bone metastases. Routine use of single fraction treatment might or might not be the preferred institutional approach. It is not entirely clear why inter-physician and inter-institution differences continue to persist despite numerous randomized trials, meta-analyses and guidelines, which recommend against more costly and inconvenient multi-fraction regimens delivering total doses of 30 Gy or more in a large number of clinical scenarios. In the present mini-review we discuss the questions of whether doctors are ignoring evidence-based medicine or whether we need additional studies targeting specifically those patient populations where recent surveys identified inconsistent treatment recommendations, e.g. because of challenging disease extent. We identify open questions and provide research suggestions, which might contribute to making radiation oncology practitioners more confident in selecting the right treatment for the right patient.

Citing Articles

Stereotactic radiotherapy for patients with bone metastases: a selected group with low rate of radiation treatment during the last month of life?.

Nieder C, Haukland E, Stanisavljevic L, Mannsaker B Radiat Oncol. 2024; 19(1):151.

PMID: 39487535 PMC: 11529251. DOI: 10.1186/s13014-024-02547-x.


Spinal Metastases of the Vertebrae: Three Main Categories of Pain.

Van den Brande R, Billiet C, Peeters M, Van de Kelft E Life (Basel). 2024; 14(8).

PMID: 39202730 PMC: 11355794. DOI: 10.3390/life14080988.


What did COVID-19 pandemics teach us about single-fraction radiotherapy for painful bone metastases-State of the art or undertreatment?.

Arsenijevic T, Stepanovic A, Milosevic-Maracic B, Poparic-Bandjur B, Miskovic I, Gavrilovic D Cancer Med. 2023; 12(15):15912-15921.

PMID: 37317639 PMC: 10469708. DOI: 10.1002/cam4.6231.


Early death after palliative radiation treatment: 30-, 35- and 40-day mortality data and statistically robust predictors.

Nieder C, Stanisavljevic L, Mannsaker B, Haukland E Radiat Oncol. 2023; 18(1):59.

PMID: 37013643 PMC: 10069056. DOI: 10.1186/s13014-023-02253-0.


Shortened Palliative Radiotherapy Results in a Lower Rate of Treatment During the Last Month of Life.

Nieder C, Haukland E, Mannsaker B Cureus. 2022; 14(1):e21617.

PMID: 35233303 PMC: 8881233. DOI: 10.7759/cureus.21617.


References
1.
Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic N . A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int J Radiat Oncol Biol Phys. 1998; 42(1):161-7. DOI: 10.1016/s0360-3016(98)00174-6. View

2.
Enright K, Clemons M, Chow E . Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. Support Care Cancer. 2003; 12(1):48-52. DOI: 10.1007/s00520-003-0548-3. View

3.
Chow E, Harris K, Fan G, Tsao M, Sze W . Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007; 25(11):1423-36. DOI: 10.1200/JCO.2006.09.5281. View

4.
Hoskin P . Scientific and clinical aspects of radiotherapy in the relief of bone pain. Cancer Surv. 1988; 7(1):69-86. View

5.
Magne N, Chargari C, Mirimanoff R, Olivier P, Vuillez J, Tubiana-Hulin M . European French-speaking study from the GEMO group on bone metastases management: a special focus on external beam radiotherapy practice survey. Support Care Cancer. 2010; 19(10):1565-72. DOI: 10.1007/s00520-010-0983-x. View